Your session is about to expire
← Back to Search
Virus Therapy
Ad5-yCD/mutTKSR39rep-hIL12 for Prostate Cancer
Phase 1
Waitlist Available
Research Sponsored by Henry Ford Health System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new cancer treatment that uses a virus to kill cancer cells. They want to find out what dose is safe and effective.
Eligible Conditions
- Prostate Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From 2024 Phase 1 trial • 15 Patients • NCT0255539767%
Chills
67%
Leukopenia
33%
ALT/SGPT increased
33%
CPK increased
33%
Urinary Frequency
33%
Diarrhea
33%
Flu-Like Symptoms
33%
Fatigue
33%
Lymphopenia
33%
Hypomagnesemia
100%
80%
60%
40%
20%
0%
Study treatment Arm
AdV Dose: 3x10e10 vp
AdV Dose: 1X10e10 vp
AdV Dose: 1x10e12 vp
AdV Dose: 1x10e11 vp
AdV Dose: 3x10e11 vp
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: SingleExperimental Treatment1 Intervention
Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 adenovirus at a dose of 1 x 10e10 to 1 x 10e12 viral particles.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ad5-yCD/mutTKSR39rep-hIL12
2015
Completed Phase 1
~30
Find a Location
Who is running the clinical trial?
Henry Ford Health SystemLead Sponsor
311 Previous Clinical Trials
2,176,351 Total Patients Enrolled
3 Trials studying Prostate Cancer
103 Patients Enrolled for Prostate Cancer
Share this study with friends
Copy Link
Messenger